

|   |  |                                |                          |
|---|--|--------------------------------|--------------------------|
| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE |  | ATTY. DOCKET NO.<br>GSL01/C    | SERIAL NO.<br>10/652,814 |
| List of Information Cited by Applicant<br>Page 1 of 11                |  | APPLICANT<br>Unger, et al.     |                          |
|   |  | FILING DATE<br>August 29, 2003 | GROUP<br>1633            |

| U.S. PATENT DOCUMENTS |  |                 |            |            |     |         |
|-----------------------|--|-----------------|------------|------------|-----|---------|
| EXAM. INITIAL         |  | DOCUMENT NUMBER | DATE       | NAME       | CLS | SUB-CLS |
| AA                    |  | 11/622,359      | 01/11/2007 | Unger      |     |         |
| AB                    |  | 2002/0142045    | 10/03/2002 | Kararli    |     |         |
| AC                    |  | 2006/0018826    | 01/26/2006 | Unger      |     |         |
| AD                    |  | 2007/0098713    | 5/3/2007   | Unger      |     |         |
| AE                    |  | 4,177,177       | 12/4/1979  | Vanderhoff |     |         |
| AF                    |  | 4,273,875       | 06/16/1981 | Manis      |     |         |
| AG                    |  | 4,304,863       | 12/08/1981 | Collins    |     |         |
| AH                    |  | 4,332,901       | 06/01/1982 | Goldstein  |     |         |
| AI                    |  | 4,336,336       | 06/22/1982 | Silhavy    |     |         |
| AJ                    |  | 4,349,629       | 09/14/1982 | Carey      |     |         |
| AK                    |  | 4,356,270       | 10/26/1982 | Itakura    |     |         |
| AL                    |  | 4,362,867       | 12/07/1982 | Paddock    |     |         |
| AM                    |  | 4,363,877       | 1/21/1982  | Goodman    |     |         |
| AN                    |  | 4,403,036       | 09/06/1983 | Hartley    |     |         |
| AO                    |  | 4,419,450       | 12/06/1983 | Dean       |     |         |
| AP                    |  | 5,013,830       | 05/07/1991 | Ohisuka    |     |         |
| AQ                    |  | 5,128,326       | 07/07/1992 | Balazs     |     |         |
| AR                    |  | 5,142,047       | 08/25/1992 | Summerton  |     |         |

| FOREIGN PATENT DOCUMENTS |  |                 |            |         |     |         |
|--------------------------|--|-----------------|------------|---------|-----|---------|
| EXAM. INITIAL            |  | DOCUMENT NUMBER | DATE       | COUNTRY | CLS | SUB-CLS |
| AS                       |  | WO 00/72679     | 02/07/2000 | PCT     |     |         |
| AT                       |  | WO 01/45764     | 06/28/2001 | PCT     |     |         |
| AU                       |  | WO 01/64164     | 09/07/2001 | PCT     |     |         |
| AV                       |  | WO 01/82964     | 11/08/2001 | PCT     |     |         |
| AW                       |  | WO 01/89579     | 11/29/2001 | PCT     |     |         |
| AX                       |  | WO 01/91808     | 06/12/2001 | PCT     |     |         |
| AY                       |  | WO 02/09735     | 02/07/2002 | PCT     |     |         |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) |   |
|--|---|
| AZ   | ABRA (1981) Biochem. Biophys. Acta 666:493-503, "Liposome disposition in vivo: dose and vesicle-size effects"         |
| AAA  | ACHARYA (1995) Computerized Medical Imaging and Graphics 19(1):3-25, "Biomedical imaging: a tutorial"                 |
| ABB  | AHMAD (2005) Anti-Cancer Drugs 16(10):1037-1043 "Targeting CK2 for cancer therapy"                                    |
| AAA  | AHMED (2002) Trend Cell Biol 12(5):226-30, "Joining the cell survival squad: an emerging role for Protein Kinase CK2" |
| AAB  | AKERMAN (2002) PNAS 99(20):12617-12621, "Nanocrystal imaging in vivo"   |

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

|  |  |                                |                          |
|--|--|--------------------------------|--------------------------|
| FORM PTO-1449  | U.S. DEPARTMENT OF<br>COMMERCE PATENT<br>AND TRADEMARK<br>OFFICE | ATTY. DOCKET NO.<br>GSL01/C    | SERIAL NO.<br>10/652,814 |
| List of Information Cited by Applicant<br>Page 2 of 11 |  | APPLICANT<br>Unger, et al.     |                          |
|  |  | FILING DATE<br>August 29, 2003 | GROUP<br>1633            |

| U.S. PATENT DOCUMENTS |  |                    |            |           |     |             |              |
|-----------------------|--|--------------------|------------|-----------|-----|-------------|--------------|
| EXAM.<br>INITIAL      |  | DOCUMENT<br>NUMBER | DATE       | NAME      | CLS | SUB-<br>CLS | FILE<br>DATE |
| BA                    |  | 5,185,444          | 02/09/1993 | Summerton |     |             |              |
| BB                    |  | 5,188,816          | 02/23/1993 | Sherry    |     |             |              |
| BC                    |  | 5,219,553          | 06/15/1993 | Kraft     |     |             |              |
| BD                    |  | 5,284,646          | 02/08/1993 | Menz      |     |             |              |
| BE                    |  | 5,358,704          | 10/25/1994 | Desreux   |     |             |              |
| BF                    |  | 5,387,124          | 05/14/2002 | Buscemi   |     |             |              |
| BG                    |  | 5,516,507          | 05/14/1996 | N'Guyen   |     |             |              |
| BH                    |  | 5,554,386          | 09/10/2000 | Groman    |     |             |              |
| BI                    |  | 5,580,960          | 12/03/1996 | Burgeson  |     |             |              |
| BJ                    |  | 5,589,466          | 12/31/1996 | Feigner   |     |             |              |
| BK                    |  | 5,593,974          | 01/14/1997 | Rosenberg |     |             |              |
| BL                    |  | 5,610,031          | 03/11/1997 | Burgeson  |     |             |              |
| BM                    |  | 5,625,040          | 04/29/1997 | Margolis  |     |             |              |
| BN                    |  | 5,626,877          | 05/06/1997 | Amsden    |     |             |              |
| BO                    |  | 5,646,248          | 07/08/1997 | Sawada    |     |             |              |
| BP                    |  | 5,648,465          | 7/15/1997  | Margolis  |     |             |              |
| BQ                    |  | 5,679,323          | 10/21/1997 | Menz      |     |             |              |

| FOREIGN PATENT DOCUMENTS |  |                    |            |         |     |            |            |
|--------------------------|--|--------------------|------------|---------|-----|------------|------------|
| EXAM.<br>INITIAL         |  | DOCUMENT<br>NUMBER | DATE       | COUNTRY | CLS | SUB<br>CLS | TRANS<br>? |
| BR                       |  | WO 02/100343       | 12/19/2002 | PCT     |     |            |            |
| BS                       |  | WO 03/087021       | 10/23/2003 | PCT     |     |            |            |
| BT                       |  | WO 03/087323       | 10/23/2003 | PCT     |     |            |            |
| BU                       |  | WO 03/087389       | 10/23/2003 | PCT     |     |            |            |
| BV                       |  | WO 98/08379        | 03/05/1998 | PCT     |     |            |            |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) |  |                 |
|--|--|-----------------|
| BW   | ALBERT (1998) Exp. Med. 188:1359-68, "Immature dendritic cells phagocytose apoptotic cells via avb5 and CD36, and cross-present antigens to cytotoxic T lymphocytes"                                       |                 |
| BX   | ALLPORT (2001) Experimental Hematology 1237-1246, "In vivo imaging of gene and cell therapies"   |                 |
| BY   | ANTISENSE RESEARCH AND APPLICATION (1988) Editor: Stanley T. Crooke, Springer-Verlag, pages 1-101  |                 |
| BBA  | AUKIHLI. (1993) J Biol. Chem. 268(4):2542-2553, "Cell- and heparin-binding domains of the hexabronchion are identified by tenascin expression proteins"  |                 |
| BBB  | BELLO (2001) Cancer Research 61:8730-36, "Simultaneous inhibition of glioma angiogenesis, cell proliferation, and invasion by a naturally occurring fragment of human metalloproteinase 2"                 |                 |
| BBC  | BENNETT (2003) Heart 89:218-224, "In-stent stenosis: pathology and implications for the development of drug-eluting stents"  |                 |
| BBD  | BRAUN (1997) Pharm. Res. 14(10):1472-78, "Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN- $\alpha$ ) in normal and transgenic mice" |                 |
| EXAMINER   |  | DATE CONSIDERED |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

|   |  |                                |                         |
|---|--|--------------------------------|-------------------------|
| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE |  | ATTY. DOCKET NO.<br>GS1.01C    | SERIAL NO.<br>10652,814 |
| List of Information Cited by Applicant<br>Page 3 of 11                |  | APPLICANT<br>Unger, et al.     |                         |
|   |  | FILING DATE<br>August 29, 2003 | GROUP<br>1633           |

| U.S. PATENT DOCUMENTS |                 |            |            |     |         |           |
|-----------------------|-----------------|------------|------------|-----|---------|-----------|
| EXAM. INITIAL         | DOCUMENT NUMBER | DATE       | NAME       | CLS | SUB-CLS | FILE DATE |
| CA                    | 5,723,335       | 03/03/1998 | Hutcherson |     |         |           |
| CB                    | 5,766,922       | 06/16/1998 | Peles      |     |         |           |
| CC                    | 5,770,565       | 06/23/1998 | Cheng      |     |         |           |
| CD                    | 5,792,743       | 08/11/1998 | Schachner  |     |         |           |
| CE                    | 5,837,313       | 11/17/1998 | Ding       |     |         |           |
| CF                    | 5,849,865       | 12/15/1998 | Cheng      |     |         |           |
| CG                    | 5,866,165       | 02/02/1999 | Liu        |     |         |           |
| CH                    | 5,872,231       | 02/16/1999 | Engvall    |     |         |           |
| CI                    | 5,891,108       | 04/06/1999 | Leone      |     |         |           |
| CJ                    | 5,902,795       | 05/11/1999 | Toole      |     |         |           |
| CK                    | 5,922,859       | 07/13/1999 | Birnstiel  |     |         |           |
| CL                    | 5,945,100       | 08/01/1999 | Fick       |     |         |           |
| CM                    | 5,962,424       | 10/05/1999 | Hallahan   |     |         |           |
| CN                    | 5,972,027       | 10/26/1999 | Johnson    |     |         |           |
| CO                    | 6,041,252       | 03/21/2000 | Walker     |     |         |           |
| CP                    | 6,071,305       | 06/06/2000 | Brown      |     |         |           |

| FOREIGN PATENT DOCUMENTS |                 |      |         |     |         |         |
|--------------------------|-----------------|------|---------|-----|---------|---------|
| EXAM. INITIAL            | DOCUMENT NUMBER | DATE | COUNTRY | CLS | SUB CLS | TRANS ? |
| CQ                       |                 |      |         |     |         |         |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  |  |
|---|--|
| CR  | BRIGGER (2002) Adv. Drug Deliv. Rev. 54:631-651, "Nanoparticles in cancer therapy and diagnosis"   |
| CS  | BRUCHEZ JR. (1998) Science 281(5385):2013-6, "Semiconductor nanocrystals as fluorescent biological labels"   |
| CT  | BULTE (2001) Nat Biotechnol 19(12):1141-7, "Magnetoendolinkers allow endosomal magnetic labeling and in vivo tracking of stem cells"   |
| CU  | CARLONI (1996) Gastroenterology 110:1127-1136, "Expression and function of integrin receptors for collagen and laminin in cultured human hepatic stellate cells"                                       |
| CV  | CLAPMAN (1996) Ultramicroscopy 62:191-213, "A characterization of dark-field imaging of colloidal gold labels in a scanning transmission X-ray microscopy"   |
| CW  | CHONN (1998) Adv. Drug Deliv. Reviews 30:73-83, "Recent advances in liposome technologies and their applications for systemic gene delivery"   |
| CX  | CLARKE (1998) Journal of Leukocyte Biology 63:163-168, "Myeloid-specific gene expression"  |
| CY  | COLIN (2000) Gene Therapy 7:139-152, "Cell delivery, intracellular trafficking and expression of an integrin-mediated gene transfer vector in tracheal epithelial cells"                               |
| CZ  | COLIN (2001) Gene Therapy 8:1643-1653, "The nuclear pore complex is involved in nuclear transfer of plasmid DNA condensed with an oligoglycine-RGD peptide containing nuclear localization properties" |
| CA  | CONDON (1996) Nature Med. 2(10):1122-1127, "DNA-based immunization by in vivo transfection of dendritic cells"   |
| CB  | COTE (1983) Proc. Nat. Acad. Sci. USA 80:2026-2030, "Generation of human monoclonal antibodies reactive with cellular antigens"  |
| EXAMINER _____ DATE CONSIDERED _____  |  |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |  |

|  |  |  |                             |                          |
|--|--|--|-----------------------------|--------------------------|
| FORM PTO-1449                          |  | U.S. DEPARTMENT OF<br>COMMERCE PATENT<br>AND TRADEMARK<br>OFFICE | ATTY. DOCKET NO.<br>GSL01/C | SERIAL NO.<br>10/652,814 |
| List of Information Cited by Applicant |  | APPLICANT<br>Unger, et al.                                       |                             |                          |
| Page 4 of 11                           |  | FILING DATE<br>August 29, 2003                                   | GROUP<br>1633               |                          |

| U.S. PATENT DOCUMENTS |  |                    |            |             |     |             |
|-----------------------|--|--------------------|------------|-------------|-----|-------------|
| EXAM.<br>INITIAL      |  | DOCUMENT<br>NUMBER | DATE       | NAME        | CLS | SUB-<br>CLS |
| DA                    |  | 6,074,609          | 06/13/2000 | Gavin       |     |             |
| DB                    |  | 6,074,659          | 06/13/2000 | Kunz        |     |             |
| DC                    |  | 6,074,673          | 06/13/2000 | Guillen     |     |             |
| DD                    |  | 6,083,996          | 07/04/2000 | Buyuktimkin |     |             |
| DE                    |  | 6,086,582          | 07/11/2000 | Altman      |     |             |
| DF                    |  | 6,086,912          | 07/11/2000 | Gilman      |     |             |
| DG                    |  | 6,106,866          | 08/22/2000 | Ranney      |     |             |
| DH                    |  | 6,110,498          | 08/29/2000 | Rudnic      |     |             |
| DI                    |  | 6,120,536          | 09/19/2000 | Ding        |     |             |
| DJ                    |  | 6,120,847          | 09/19/2000 | Yang        |     |             |
| DK                    |  | 6,121,231          | 09/19/2000 | Petit       |     |             |
| DL                    |  | 6,124,260          | 09/26/2000 | Sharifi     |     |             |
| DM                    |  | 6,140,117          | 10/31/2000 | Milbradt    |     |             |
| DN                    |  | 6,142,939          | 11/07/2000 | Eppstein    |     |             |
| DO                    |  | 6,153,729          | 11/28/2000 | Stein       |     |             |
| DP                    |  | 6,159,142          | 12/12/2000 | Alt         |     |             |
| DQ                    |  | 6,159,467          | 12/12/2000 | Chung       |     |             |

| FOREIGN PATENT DOCUMENTS |  |                    |      |         |     |             |
|--------------------------|--|--------------------|------|---------|-----|-------------|
| EXAM.<br>INITIAL         |  | DOCUMENT<br>NUMBER | DATE | COUNTRY | CLS | SUB-<br>CLS |
| DR                       |  |                    |      |         |     | TRANS ?     |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) |   |
|--|---|
| DS   | DANIOTTI (1994) Cellular & Molecular Biology Research 40(5/6):431-439, see abstract, "Cloning and Expression of Gene Coding for Protein Kinase CK2 Alpha and Beta Subunits in Zebrafish"                              |
| DT   | DONNELL (2003), Int. J. Parasitol 33:457-67, "Technical and regulatory hurdles for DNA vaccines"  |
| DU   | DRAZBA (1990) Dev. Biol. 138(1):82-93, "The role of cell adhesion molecules in neurite outgrowth on Mueller cells"  |
| DV   | DUBERTRET ET AL. (2002) Science 298:1759-1762, "In Vivo Imaging of Quantum Dots Encapsulated in Phospholipid Micelles"  |
| DW   | FATTORI (2003) The Lancet 361(1):247-249, "Drug-eluting stents in vascular intervention"  |
| DX   | FAUST (2000) Head & Neck 22:341-346 "Antisense oligonucleotides against protein kinase CK2-alpha inhibit growth of squamous cell carcinoma of the head and neck in vitro"   |
| DY   | FELDMAN (2000) J. of Long-Term Effects of Medical Implants, 10(1/2):47-68, "Stent-Based Gene Therapy"   |
| DZ   | FLAHERTY (1995) Mol Cell Biol 65:27a, Tech Bulletin #425, <a href="http://www. dbbio.com">http://www. dbbio.com</a> , "Phenotypic modulation of aortic smooth muscle cells using optimized cell culture environments" |
| DAA  | FOGED (2002) Pharm Res. 19(3):229-238, "Targeting vaccines to dendritic cells"  |

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

|   |  |                             |                          |
|---|--|-----------------------------|--------------------------|
| FORM PTO-1449<br><br>List of Information Cited by Applicant<br><br>Page 5 of 11 | U.S. DEPARTMENT OF<br>COMMERCE PATENT<br>AND TRADEMARK<br>OFFICE | ATTY. DOCKET NO.<br>GSL01/C | SERIAL NO.<br>10/652,814 |
|   | APPLICANT<br>Unger, et al.                                       |                             |                          |
|   | FILING DATE:<br>August 29, 2003                                  | GROUP<br>1633               |                          |
|   |  |                             |                          |

| U.S. PATENT DOCUMENTS |                    |            |            |     |             |              |
|-----------------------|--------------------|------------|------------|-----|-------------|--------------|
| EXAM-<br>INITIAL      | DOCUMENT<br>NUMBER | DATE       | NAME       | CLS | SUB-<br>CLS | FILE<br>DATE |
| EA                    | 6,174,867          | 01/16/2001 | Hindsgaul  |     |             |              |
| EB                    | 6,204,054          | 03/20/2001 | Sutton     |     |             |              |
| EC                    | 6,232,287          | 05/15/2001 | Ruoslahti  |     |             |              |
| ED                    | 6,235,313          | 05/22/2001 | Mathiowitz |     |             |              |
| EE                    | 6,245,349          | 06/12/2001 | Viv        |     |             |              |
| EF                    | 6,251,079          | 06/26/2001 | Gambac     |     |             |              |
| EG                    | 6,258,121          | 07/02/2001 | Yang       |     |             |              |
| EH                    | 6,283,947          | 09/04/2001 | Mirzace    |     |             |              |
| EI                    | 6,283,949          | 09/04/2001 | Roorda     |     |             |              |
| EJ                    | 6,287,792          | 09/11/2001 | Pardridge  |     |             |              |
| EK                    | 6,296,832          | 10/02/2001 | Ruoslahti  |     |             |              |
| EL                    | 6,301,660          | 10/09/2001 | Benson     |     |             |              |
| EM                    | 6,303,114          | 10/16/2001 | Metzger    |     |             |              |
| EN                    | 6,303,137          | 10/16/2001 | Dittgen    |     |             |              |
| EO                    | 6,303,573          | 10/16/2001 | Ruoslahti  |     |             |              |
| EP                    | 6,306,365          | 10/23/2001 | Ruoslahti  |     |             |              |
| EQ                    | 6,309,375          | 10/30/2001 | Glines     |     |             |              |

| FOREIGN PATENT DOCUMENTS |                    |      |         |     |             |            |
|--------------------------|--------------------|------|---------|-----|-------------|------------|
| EXAM-<br>INITIAL         | DOCUMENT<br>NUMBER | DATE | COUNTRY | CLS | SUB-<br>CLS | TRANS<br>? |
| ER                       |                    |      |         |     |             |            |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) |   |
|--|---|
| ES   | FRECHET (1994) Science 263(5154):1710-5, "Functional polymers and dendrimers: reactivity, molecular architecture, and interfacial energy"   |
| ET   | FROEHLER (1988) Nucleic Acids Res 16(4):4831-4839, "Phosphoramidate analogues of DNA: synthesis and thermal stability of heteroduplexes"  |
| EU   | GAPANY (1995) Mol Med. 1(6):659-66, "Association of elevated protein kinase CK2 activity with aggressive behavior of squamous cell carcinoma of the head and neck"  |
| EV   | GAUTSCHI (2001) J. of National Cancer Institute 93(6):463-471 "Activity of a Novel bcl-2/bcl-xL-Bispecific Antisense Oligonucleotide Against Tumors of Diverse Histologic Origin"                         |
| EW   | GLINSKY (2001) Cancer Research 61:4851-57, "The role of Thomas Friedrich antigen in adhesion of human breast and prostate cancer cells to the endothelium"  |
| EX   | GRAUER (2002) J. Histochem Cell Biol 117:35 1-362, "Analysis of maturation states of rat bone marrow-derived dendrite cells using an improved culture technique"  |
| EY   | GRAYSON (2001) Chem. Rev. 101(12):3819-68, "Convergent dendrons and dendrimers: from synthesis to applications"   |
| EZ   | GUERMONPREZ (2002) Ann. Rev. Immunol. 20:621-27, "Antigen presentation and T cell stimulation by dendritic cells"   |
| EAA  | HANDBOOK OF TARGETED DELIVERY (1995) CRC Press, Edited by Vladimir P. Torchilin, Ph.D., pages 3-101, 103-117, 119-147, 149-173, 177-192, 218-227, 259-288, 365-384, 429-443, 487-500, 523-552 and 597-609 |

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

|   |  |                                |                          |
|---|--|--------------------------------|--------------------------|
| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE |  | ATTY. DOCKET NO.<br>GSL01/C    | SERIAL NO.<br>10/652,814 |
| List of Information Cited by Applicant                                |  | APPLICANT<br>Unger, et al.     |                          |
| Page 6 of 11  |  | FILING DATE<br>August 29, 2003 | GROUP<br>1633            |

| U.S. PATENT DOCUMENTS |                    |            |                  |     |             |              |
|-----------------------|--------------------|------------|------------------|-----|-------------|--------------|
| EXAM-<br>INITIAL      | DOCUMENT<br>NUMBER | DATE       | NAME             | CLS | SUB-<br>CLS | FILE<br>DATE |
| FA                    | 6,309,380          | 10/30/2001 | Larson           |     |             |              |
| FB                    | 6,309,410          | 10/30/2001 | Kutzma           |     |             |              |
| FC                    | 6,317,629          | 11/13/2001 | Haak             |     |             |              |
| FD                    | 6,319,426          | 11/20/2001 | Bawendi          |     |             |              |
| FE                    | 6,326,144          | 12/04/2001 | Bawendi          |     |             |              |
| FF                    | 6,342,250          | 01/29/2002 | Masters          |     |             |              |
| FG                    | 6,346,272          | 02/12/2002 | Viegas           |     |             |              |
| FH                    | 6,350,780          | 02/25/2002 | Garst            |     |             |              |
| FI                    | 6,352,972          | 03/05/2002 | Nimni            |     |             |              |
| FJ                    | 6,353,090          | 03/05/2002 | Pierschbacher    |     |             |              |
| FK                    | 6,358,556          | 03/19/2002 | Ding             |     |             |              |
| FL                    | 6,379,382          | 04/30/2002 | Yang             |     |             |              |
| FM                    | 6,387,124          | 05/14/2002 | Buscemi          |     |             |              |
| FN                    | 6,387,397          | 05/14/2002 | Chen             |     |             |              |
| FO                    | 6,395,253          | 05/28/2002 | Levy et al.      |     |             |              |
| FP                    | 6,404,705          | 06/11/2002 | Watanabee        |     |             |              |
| FQ                    | 6,406,745          | 06/18/2002 | Talton, James D. |     |             |              |

| FOREIGN PATENT DOCUMENTS |                    |      |         |     |             |            |
|--------------------------|--------------------|------|---------|-----|-------------|------------|
| EXAM-<br>INITIAL         | DOCUMENT<br>NUMBER | DATE | COUNTRY | CLS | SUB-<br>CLS | TRANS<br>? |
| FR                       |                    |      |         |     |             |            |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) |   |
|--|---|
| FS   | HARADA (2001) European Journal of Pharmaceutical Sciences 13:35-42, "Physiochemical Properties and Nucleic Resistance of Antisense/OligodeoxynucleotideS Entrapped in the Core of Polyion Complex Micelles Composed of Poly(ethylene Glycol)-Poly(L-Lysine) Block Copolymers" |
| FT   | HASAN (1999) J Immunol Meth 229:1-22, "Nucleic acid immunization: concepts and techniques associated with third generation vaccines"  |
| FU   | HEATH (1998) Nature 393:730-1, "Fullerenes: C60's smallest cousin"  |
| FV   | HERMANSON (1996) Bioconjugate Techniques, Academic Press, Inc.  |
| FW   | HORNBERGER (2000) Circ Res. 87(6):508-15, "Synthesis of extracellular matrix and adhesion through 131 integrins are critical for fetal ventricular myocyte proliferation"   |
| FX   | HUNT (1992) J. Biomed. Mat. Res. 26:819-828, "Stimulation of neutrophil movement by metal ions"   |
| FY   | HUSSAIN (2000) Adv. Drug Deliv. Rev. 43:95-100, "Ligand-mediated tissue specific drug delivery"   |
| FZ   | HUSSAIN (2004) J. of Controlled Release 99:139-155 "A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides"   |
| FAA  | INABA (1995) Cell Immunol. 163:148-156, "Tissue distribution of the DEC-205 protein that is detected by the monoclonal antibody NLDC-145"   |

|   |                 |
|---|-----------------|
| EXAMINER  | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |                 |

|   |  |                                |                          |
|---|--|--------------------------------|--------------------------|
| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE |  | ATTY. DOCKET NO.<br>GSL01/C    | SERIAL NO.<br>10/652,814 |
| List of Information Cited by Applicant<br>Page 7 of 11                |  | APPLICANT<br>Unger, et al.     |                          |
|   |  | FILING DATE<br>August 29, 2003 | GROUP<br>1633            |

| U.S. PATENT DOCUMENTS |                 |            |               |     |         |           |  |
|-----------------------|-----------------|------------|---------------|-----|---------|-----------|--|
| EXAM. INITIAL         | DOCUMENT NUMBER | DATE       | NAME          | CLS | SUB-CLS | FILE DATE |  |
| GA                    | 6,413,942       | 07/02/2002 | Fcigner       |     |         |           |  |
| GB                    | 6,416,778       | 07/09/2002 | Ragavan       |     |         |           |  |
| GC                    | 6,440,738       | 08/27/2002 | Wyatt         |     |         |           |  |
| GD                    | 6,455,307       | 09/24/2002 | McKay         |     |         |           |  |
| GE                    | 6,475,995       | 11/05/2002 | Roy           |     |         |           |  |
| GF                    | 6,482,410       | 11/19/2002 | Crossin       |     |         |           |  |
| GG                    | 6,506,411       | 01/14/2003 | Hunter et al. |     |         |           |  |
| GH                    | 6,528,481       | 03/04/2003 | Burg          |     |         |           |  |
| GI                    | 6,607,916       | 08/19/2003 | Freier        |     |         |           |  |

| FOREIGN PATENT DOCUMENTS |                 |      |         |     |         |         |
|--------------------------|-----------------|------|---------|-----|---------|---------|
| EXAM. INITIAL            | DOCUMENT NUMBER | DATE | COUNTRY | CLS | SUB-CLS | TRANS ? |
| GI                       |                 |      |         |     |         |         |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  |  |
|---|--|
| GIK   | INACTIVE INGREDIENT GUIDE (1996) Division of Drug Information Resources, FFDA  |
| GL  | INTERNATIONAL SEARCH REPORT (PCT/US03/10850) from corresponding PCT application dated 11 December 2003 (7 pages).  |
| GM  | INTERNATIONAL SEARCH REPORT (PCT/US03/10854) from corresponding PCT application dated 05 December 2003 (6 pages).  |
| GN  | JACOB Cancer Research (1999) 59:4453-57, "Osteonecrosis promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone" |
| GO  | JAIN Sci. American (1994) 7:58-65, "Barriers to drug delivery in solid tumors"   |
| GP  | JANeway (2002) Ann. Rev. Immunology 20:197-216, "Innate immune recognition"  |
| GQ  | JOHANSEN (2000) Eur. J. Pharm. Biopharm. 50:129-146, "Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination"          |
| GR  | JOHNSTONE, R., Nature Rev. Drug Disc. (2002) 1:287-299, "Histone-deacetylase inhibitors: novel drugs for the treatment of cancer"                          |
| GS  | KLINMAN (1998) J. Immunol. 160:2388-2392, "Contribution of cells at the site of DNA vaccination to the generation of antigen-specific immunity and memory" |
| GT  | KOHLER (1975) Nature 256:495-497, "Continuous cultures of fused cells secreting antibodies of predefined specificity"                                      |
| GU  | KOLTSEV (2000) PNAS 97(26):14046-14051 "DNA condensation in two dimensions"  |
| GV  | KOUKOULIS (1991) Tenascin in normal, reactive, hyperplastic and neoplastic tissues: biologic and pathologic implications. <i>Hu Pathol</i> 22:636-643.     |
| GW  | KOZBOR (1983) Immunology Today 4:72, "The production of monoclonal antibodies from human lymphocytes"  |
| GX  | KRIEG (2002) Ann. Rev. Immunol. 20:700-60, "CpG motifs in bacterial DNA and their immune effects"  |
| GY  | KRONENWETT (2000) Stem Cells 18(5):320-330, "The role of cytokines and adhesion molecules for mobilization of peripheral stem cells"                       |
| EXAMINER  | DATE CONSIDERED  |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |  |

|   |  |                                |                         |
|---|--|--------------------------------|-------------------------|
| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE |  | ATTY. DOCKET NO.<br>GSL01/C    | SERIAL NO.<br>10652,814 |
| List of Information Cited by Applicant<br>Page 8 of 11                |  | APPLICANT<br>Unger, et al.     |                         |
|   |  | FILING DATE<br>August 29, 2003 | GROUP<br>1633           |

| U.S. PATENT DOCUMENTS |                    |           |            |     |             |              |
|-----------------------|--------------------|-----------|------------|-----|-------------|--------------|
| EXAM.<br>INITIAL      | DOCUMENT<br>NUMBER | DATE      | NAME       | CLS | SUB-<br>CLS | FILE<br>DATE |
| HA                    | 6,797,685          | 9/28/2004 | Zhu et al. |     |             |              |

| FOREIGN PATENT DOCUMENTS |                    |      |         |     |             |            |
|--------------------------|--------------------|------|---------|-----|-------------|------------|
| EXAM-<br>INITIAL         | DOCUMENT<br>NUMBER | DATE | COUNTRY | CLS | SUB-<br>CLS | TRANS<br>? |
| HB                       |                    |      |         |     |             |            |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) |   |
|--|---|
| HC   | LACKEY (2002) <i>Bioconjugate Chem.</i> 13, 996-1001, "A biomimetic pH-responsive polymer directs endosomal release and intracellular delivery of an endocytosed antibody complex"                                  |
| HD   | LAFLEUR (1997) <i>J. Biol. Chem.</i> 272(52):32798-32803, "Aortic smooth muscle cells interact with tenascin-C through its fibronectin-like domain"   |
| HE   | LAKKARAJU (2001) <i>J. Biol. Chem.</i> 276(34):32000-007, "Neurons are protected from excitotoxic death by p53 antisense oligonucleotides delivered in anionic liposomes"   |
| HF   | LARREGINA (1997), <i>Immunol.</i> 91:303-13, "Pattern of cytokine receptors expressed by human dendritic cells migrated from dermal explants"   |
| HG   | LEBEDEVA (2000) <i>European J. of Pharmaceutics and Biopharmaceutics</i> 50:101-119 "Cellular delivery of antisense oligonucleotides"   |
| HH   | LEE <i>Crit. Rev. Ther. Drug Carr. Sys.</i> , (1997) 14:2 173-206, "Lipid vector systems for gene transfer"   |
| HI   | LIPSCOMB (2002), <i>Physiol. Rev.</i> 82:97-130, "Dendritic cells: immune regulators in health and disease"   |
| HJ   | LIU (2003), <i>J. Int. Med.</i> 253:402-410, "DNA vaccines: a review"   |
| HK   | LIVANT (2000), <i>Cancer Res.</i> 60:309-320, "Anti-sense, antitumorigenic, and Antimetastatic Activities of the PHSNC Sequence in Prostate Carcinoma"  |
| HL   | MANOME (1998) <i>Immunol.</i> 98:481-490, "Simple chemicals can induce maturation and apoptosis of dendritic cells"   |
| HM   | MARAGOU (1996) <i>Oral Disease</i> , 20-6, "Alteration of integrin expression in oral squamous cell carcinomas"   |
| HN   | MARTIN (1997), <i>Development</i> 124(19):3909-3917, "Integrins mediate adhesion to agrin and modulate agrin signaling"   |
| HO   | MARTIN (2000) <i>Int. J. Rad. Oncol. Biophys.</i> 47(2):277-90 " TGF- $\beta$ 1 and radiation fibrosis: a master switch and a specific therapeutic target?"   |
| HP   | MERDAN (2002) <i>Adv Drug Deliv Rev</i> 54:715-758, "Prospects for cationic polymers in gene and oligonucleotide therapy against cancer"  |
| HQ   | MICIC "Size-dependent spectroscopy of InP quantum dots" <i>J. Phys. Chem. B</i> , 101(25):4904-12, 1997   |
| HR   | MILLER (1979) <i>Biochem.</i> 18:5134-5143, "Nonionic nucleic acid analogs. Synthesis and characterization of dideoxyribonucleoside methylphosphonates"   |
| HS   | MILLER (1980) <i>J. Biol. Chem.</i> 255:9659-9665, "Oligothymidylate analogues having stereoregular, alternating methylphosphonate/phosphodiester backbones"  |
| HT   | MOHACSI (1997), <i>J Heart Lung Transplant</i> 16:484-92 " Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial proliferation stimulated by PDGF or ECGF." |
| HU   | MOINGEON (2002), <i>J. Biotech.</i> 98:189-98, "Strategies for designing vaccines eliciting Th1 responses in humans"  |
| HV   | NABI (2003) <i>J Cell Biology</i> 161(4):673-77, "Caveolae/raft-dependent endocytosis"  |

EXAMINER

DATE CONSIDERED

\*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

|   |  |                                |                          |
|---|--|--------------------------------|--------------------------|
| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE |  | ATTY. DOCKET NO.<br>GSL01/C    | SERIAL NO.<br>10/652,814 |
| List of Information Cited by Applicant<br>Page 9 of 11                |  | APPLICANT<br>Unger, et al.     |                          |
|   |  | FILING DATE<br>August 29, 2003 | GROUP<br>1633            |

| U.S. PATENT DOCUMENTS |    |                 |      |      |     |           |
|-----------------------|----|-----------------|------|------|-----|-----------|
| EXAM. INITIAL         |    | DOCUMENT NUMBER | DATE | NAME | CLS | SUB-CLS   |
|                       | IA |                 |      |      |     | FILE DATE |

| FOREIGN PATENT DOCUMENTS |    |                 |      |         |     |         |
|--------------------------|----|-----------------|------|---------|-----|---------|
| EXAM. INITIAL            |    | DOCUMENT NUMBER | DATE | COUNTRY | CLS | SUB-CLS |
|                          | IB |                 |      |         |     | TRANS ? |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  |    |  |                 |  |  |  |
|---|----|--|-----------------|--|--|--|
|   | IC | NIE "Probing single molecules and single nanoparticles by surface-enhanced raman scattering" Science 275(5303):1102-6, 1997  |                 |  |  |  |
|   | ID | NIELSEN (1991) Science 254:1497-1500, "Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide"  |                 |  |  |  |
|   | IE | NORDE (1997) Polymeric Dispersions: Principles and Applications pp. 541-555 Kluwer Academic Publishers, Netherlands "Interaction of Proteins with Polymeric and Other Colloids"  |                 |  |  |  |
|   | IP | NORMAN (2000), Gene Ther. 7:1425-1430, "Liposome-mediated, nonviral gene transfer induces a systemic inflammatory response"  |                 |  |  |  |
|   | IG | O'HAGAN (2001), J Virol 75(19):9037-43, "Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines"  |                 |  |  |  |
|   | II | OMIDI (2003) J. of Drug Targeting 11(6):311-323 "Toxicogenomics of Non-viral Vectors for Gene Therapy: A Microarray Study of Lipofectin- and Oligofectamine-induced Gene Expression Changes in Human Epithelial Cells"               |                 |  |  |  |
|   | II | OTTEN (2000) Intervirology 43:227-232, "Relative potency of cellular and humoral immune responses induced in DNA vaccination"  |                 |  |  |  |
|   | IJ | PELKMAN (2001) Nature Cell Biology (3):473-83 "Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER"   |                 |  |  |  |
|   | IK | PHAM (2000) Am. J. Phys. 279(6):H2916-26, "Striated muscle-specific $\beta$ 1-integrin and FAK are involved in cardiac myocyte hypertrophic response pathways"   |                 |  |  |  |
|   | IL | PITHA (1970) Biochim. Biophys. Acta 204:39-48, "Polyvinyluracil: the preparation and interactions with adenosine derivatives"  |                 |  |  |  |
|   | IM | PITHA (1970) Biopolymers 9:965-977, "Preparation and properties of poly-9-vinyl-adenosine"   |                 |  |  |  |
|   | IN | QUINTANAR-GUERRERO (1996) International J. of Pharmaceutics 143:133-141 "Influence of stabilizing agents and preparative variables on the formation of poly(D,L-lactic acid) nanoparticles by an emulsification-diffusion technique" |                 |  |  |  |
|   | IO | REISS (1997), Breast Cancer Research & Treatment 45(1):81-95, "Transforming growth factor- $\beta$ 1 in breast cancer, a working hypothesis"   |                 |  |  |  |
|   | IP | RICHARDSON (2002) Stem Cells 20:105-118 "Gene repair and transposon-mediated gene therapy"   |                 |  |  |  |
|   | IQ | ROUSSELLE (2000) Molecular Pharmacology, 57:679-686, "New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy"  |                 |  |  |  |
|   | IR | RUDGINSKY (2001), Gene Ther. 4(4):347-355, "Antitumor activity of cationic lipid complexed with immunostimulatory DNA"   |                 |  |  |  |
|   | IS | SASAKI (2001), Nature Biotech 19:543-47, "Apoptosis-mediated enhancement of DNA-raised immune responses by mutant caspases"  |                 |  |  |  |
|   | IT | SAZANI (2002) Nature Biotechnology, 20:1228-33, "Systemically delivered antisense oligomers upregulate gene expression in mouse tissue"  |                 |  |  |  |
|   | IU | SCHEULE (2000) Adv Drug Deliv Rev 44:1 19-134, "The role of CpG motifs in immunostimulation and gene therapy"  |                 |  |  |  |
| EXAMINER  |    |  | DATE CONSIDERED |  |  |  |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |    |  |                 |  |  |  |

|   |  |                                |                          |
|---|--|--------------------------------|--------------------------|
| FORM PTO-1449   | U.S. DEPARTMENT OF<br>COMMERCE PATENT<br>AND TRADEMARK<br>OFFICE | ATTY. DOCKET NO.<br>GSL01/C    | SERIAL NO.<br>10/652,814 |
| List of Information Cited by Applicant<br>Page 10 of 11 |  | APPLICANT<br>Unger, et al.     |                          |
|   |  | FILING DATE<br>August 29, 2003 | GROUP<br>1633            |

| U.S. PATENT DOCUMENTS |                    |      |      |     |             |              |
|-----------------------|--------------------|------|------|-----|-------------|--------------|
| EXAM.<br>INITIAL      | DOCUMENT<br>NUMBER | DATE | NAME | CLS | SUB-<br>CLS | FILE<br>DATE |
| JA                    |                    |      |      |     |             |              |

| FOREIGN PATENT DOCUMENTS |                    |      |         |     |             |            |
|--------------------------|--------------------|------|---------|-----|-------------|------------|
| EXAM.<br>INITIAL         | DOCUMENT<br>NUMBER | DATE | COUNTRY | CLS | SUB-<br>CLS | TRANS<br>? |
| JB                       |                    |      |         |     |             |            |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) |  |
|--|--|
| JC   | SCHREDER "CdTe/CdS clusters with 'core shell' structure in colloids and films: The path of formation and thermal breakup" J. Phys. Chem. B., 104(8):1677-85, 2000  |
| JD   | SENGER, Ann NY Acad Sci 760:83-100, "Osteopontin at the tumor/host interface"  |
| JE   | SHOJI (2004) Current Pharmaceutical Design 10(7):785-796 "Current Status of Delivery Systems to Improve Target Efficacy of Oligonucleotides"   |
| JF   | SIMPSON (2001) J Biol. Chem. 276(21):17949-57, "Hyaluronan synthase elevation in metastatic prostate carcinoma cells correlates with hyaluronan surface retention, a prerequisite for rapid adhesion to bone marrow endothelial cells" |
| JG   | SIMPSON (2002) Amer. J. of Path 161(3):849-857, "Inhibition of Prostate Tumor Cell Hyaluronan Synthesis impairs Subcutaneous Growth and Vascularization in Immunocompromised Mice"   |
| JH   | SINGH (2002), Pharm Res. 19(6):715-28, "Recent advances in vaccine adjuvants"  |
| JI   | SLATON (2004) Mol. Cancer Res. 2(12):712-721 "Induction of Apoptosis by Antisense CK2 in Human Prostate Cancer Xenograft Model"  |
| JJ   | SPONSEL (1996) Am J. Phys (Cell Physiol. 40) 271:e721-c272, "Mechanisms of recovery from mechanical injury of cultured rat hepatocytes"  |
| JK   | STOITZNER (2001), J Invest Dermatol 118:117-125, "A closeup view of migrating langerhans cells in the skin"  |
| JL   | STORM (1998), Clin. Can. Res. 4:111-15, "Doxorubicin entrapped in sterically stabilized liposomes: effects on bacterial blood clearance capacity of the mononuclear phagocyte system"  |
| JM   | TAWFIK (2001) Histo and Histopathol 16:573-82, "Protein kinase CK2 signal in neoplasia"  |
| JN   | TIMARES (2003), J Immunol 170:5483-5490 "Drug-inducible, dendrite cell-based genetic immunization"   |
| JO   | TOUSIGNANT (2000), Hu. Gene Ther. 11:2493-2513, "Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid: plasmid DNA complexes in mice"   |
| JP   | Transdermal and Topical Drug Delivery Systems (Tapash K. Ghosh, ed. Interpharm Press, Inc. 1997)   |
| JQ   | TSAI (2002) J. Biol. Chem 277(35):31826-33, "Regulation of histone deacetylase by protein CK2"   |
| JR   | TUXHORN, J Urol. (2001) 166:2472-2483, "Reactive stroma in prostate tumor progression"   |
| JS   | UNGER (2002) 43:57, "Effective chemotherapeutic activity by sub50-nm nanocapsule antisense to protein kinase CK2 for eradication of in vitro tumor nests via targeted cellular-mediated endocytosis"                                   |
| JT   | UNGER (2003) AACR Proceedings, 44:1473, Abstract only: "Antisense formulation via sub50-nm nanoencapsulation enhances effectiveness of problematic medicinal chemistry for tumor-specific antisense to PK CK2"                         |
| JU   | United States Pharmacopeia, 1981 United States Pharmacopeia Dispensing Information   |
| JV   | VARNER (1995) Cell Ad Commun 3:367-374, "The integrin avb3:angiogenesis and apoptosis"   |
| JW   | VIGUSHIN (2002) Anti-cancer drugs, 13:1-13, "Histone deacetylase inhibitors in cancer treatment"   |

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

|   |  |                                |                          |
|---|--|--------------------------------|--------------------------|
| FORM PTO-1449   | U.S. DEPARTMENT OF<br>COMMERCE PATENT<br>AND TRADEMARK<br>OFFICE | ATTY. DOCKET NO.<br>GSL01/C    | SERIAL NO.<br>10/652,814 |
| List of Information Cited by Applicant<br>Page 11 of 11 |  | APPLICANT<br>Unger, et al.     |                          |
|   |  | FILING DATE<br>August 29, 2003 | GROUP<br>1633            |

| U.S. PATENT DOCUMENTS |                    |      |      |     |             |              |
|-----------------------|--------------------|------|------|-----|-------------|--------------|
| EXAM.<br>INITIAL      | DOCUMENT<br>NUMBER | DATE | NAME | CLS | SUB-<br>CLS | FILE<br>DATE |
| KA                    |                    |      |      |     |             |              |
| KB                    |                    |      |      |     |             |              |
| KC                    |                    |      |      |     |             |              |
| KD                    |                    |      |      |     |             |              |
| KE                    |                    |      |      |     |             |              |
| KF                    |                    |      |      |     |             |              |
| KG                    |                    |      |      |     |             |              |
| KH                    |                    |      |      |     |             |              |
| KI                    |                    |      |      |     |             |              |
| KJ                    |                    |      |      |     |             |              |
| KK                    |                    |      |      |     |             |              |
| KL                    |                    |      |      |     |             |              |
| KM                    |                    |      |      |     |             |              |
| KN                    |                    |      |      |     |             |              |
| KO                    |                    |      |      |     |             |              |
| KP                    |                    |      |      |     |             |              |
| KQ                    |                    |      |      |     |             |              |

| FOREIGN PATENT DOCUMENTS |                    |      |         |     |            |            |
|--------------------------|--------------------|------|---------|-----|------------|------------|
| EXAM.<br>INITIAL         | DOCUMENT<br>NUMBER | DATE | COUNTRY | CLS | SUB<br>CLS | TRANS<br>? |
| KR                       |                    |      |         |     |            |            |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) |  |
|--|--|
| KS   | VIRMANI (2002), Circulation 106:2649-2651, "Mechanism of late stent restenosis after implantation of a paclitaxel derive- eluting polymer stent system in humans"                            |
| KT   | WANG (1995) Am. J Surg. 170(5) 502-5, "The effect of thrombospondin on oral squamous carcinoma invasion of collagen"   |
| KU   | WANG (2005) Molecular and Cellular Biochemistry 274:77-84 "Downregulation of CK2 induces apoptosis in cancer cells - A potential approach to cancer therapy"                                 |
| KV   | WEERATNA (2000), Intervirology 43:2128-226, "Optimization strategies for DNA vaccines".  |
| KW   | WERLING (1999), J Leuko Biol 66:50-68, "Involvement of caveolae in the uptake of respiratory syncytial virus antigen by dendritic cells"   |
| KX   | WOLFERT (1996) Gene Therapy 3:269-273 "Atomic force microscopic analysis of the influence of the molecular weight of poly(L-lysine on the size of polyelectrolyte complexes formed with DNA" |
| KY   | WONG (2000) Chemistry of Protein Conjugation and Cross-Linking, CRC Press, Inc.  |
| KZ   | YAN (1998) J. Histochem Chem 46(1):3-10 "SPARC is expressed by ganglion cells and astrocytes in bovine retina"   |
| KAA  |  |
| KBB  |  |

EXAMINER \_\_\_\_\_ DATE CONSIDERED \_\_\_\_\_

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.